Page 3 - Bharat Biotech

Covaxin is safe for 2-18 age group in phase 2, 3 trials: Bharat Biotech

A total of 374 subjects reported either mild or moderate severity symptoms, with 78.6% getting resolved within a day, says Hyderabad-based vaccine maker

Covaxin found to be safe for children in phase 2, 3 trials: Bharat Biotech

The clinical trials conducted on the paediatric population between June-September 2021 have shown robust safety, reactogenicity, and immunogenicity, says Hyderabad-based firm

Vaccine makers bet global demand, boosters will drive growth next year

Domestic demand had fallen after cases began to decline. Omicron surge may reverse the trend

Bharat Biotech targets one billion doses of intranasal vaccine annually

The Hyderabad-based vaccine maker has already approached the Drug Controller General of India (DCGI) for approval to conduct phase-III trials of its intranasal vaccine

LIVE: Maharashtra sees 26 more cases of Omicron; night curfew in Kerala

Telangana reports 12 new Omicron cases in the last 24 hours

Bharat Biotech eyes 1 billion doses of nasal Covid-19 vaccine in 2022

Looks for global partners to produce and distribute vaccine - BBV154

Bharat Biotech seeks approval for Phase 3 trials of intranasal vaccine

Bharat Biotech has sought the approval of the Drug Controller General of India (DCGI) to conduct Phase 3 trials of its Covid-19 intranasal vaccine

Bharat Biotech seeks nod for phase-3 clinical trials of nasal vaccine

The Hyderabad-based vaccine maker conducted phase 2 trials on 650 volunteers

Covid-19 vaccine Covaxin's shelf life extended to 12 months: Bharat Biotech

The multi-dose vial policy saves money for procurement agencies by reducing the cold chain logistics

Bharat Biotech seeks trial for intranasal Covid vaccine booster

'We have submitted phase 3 clinical trial application to DCGI (Drugs Controller General of India)," a Bharat Biotech spokesperson said

Covaxin for 2-18 yrs: Examining Expert Committee recommendations, says govt

Union Minister of State for Health Bharati Pravin Pawar shared the information through a written reply in Rajya Sabha

Bharat Biotech resumes Covaxin export with 'long-pending orders' in Nov

The Centre allowed commercial exports of Covaxin last week

'Long pending orders executed': Bharat Biotech resumes exports of Covaxin

India restarted on Friday exports of Covid-19 shots to COVAX for the first time since April

Bharat Biotech updates Covaxin efficacy to 65.2% against Delta variant

Experts say more real-world studies are required now

Centre allows Bharat Biotech to begin commercial exports of Covaxin

Bharat Biotech made 55 million doses of Covaxin in October, and aims to make 80 million doses in December.

Covaxin doses 50% effective against symptomatic Covid: Real-world study

Research does not estimate vaccine effectiveness against hospitalisation, severe disease, and death.

India-made Covid-19 vaccine Covaxin now on UK's approved travel list

Earlier this month, the Bharat Biotech manufactured Covaxin had received its WHO EUL status

Vaccine makers ramp up production capacities despite low current demand

Booster shot, children vaccination, exports can spike demand in the future

Developing Covaxin was an enormous challenge: Bharat Biotech

Bharat Biotech Director V Krishna Mohan said said there were no vaccines when Covid-19 hit India, and the world

Bharat Biotech's Covid-19 vaccine Covaxin gets mixed review from Lancet

Extrapolating from the report, Lancet said 'two doses offer 77.8 per cent protection against symptomatic Covid-19'.